eXoZymes reported wider GAAP operating and net losses in Q1 FY2026 versus prior year, reflecting intensified R&D and operational investments as a pre-revenue biotech, with operating cash burn accelerating amid working capital insufficient for a 12-month runway.
Key takeaways
GAAP operating loss expanded 22.4% to -$2.4M from -$2.0M in Q1 FY2025, driven by increased R&D and staffing to expand production capabilities.
Net loss deepened 27.7% to -$2.4M from -$1.9M year-over-year, as the Company funds synthetic biology platform development.
Diluted EPS deteriorated 27.3% to -$0.28 from -$0.22, highlighting the impact of higher losses on per-share metrics.
Capital expenditures rose to $58K from $31K, supporting laboratory equipment needs for production expansion.
Free cash flow reached -$1.6M, as operating cash outflows exceeded modest capex amid ongoing working capital drawdown.